Literature DB >> 4700496

Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses.

P M Henson, H L Spiegelberg.   

Abstract

The ability of human myeloma proteins of different classes and subclasses and of macroglobulins (all aggregated with bis-diazotized benzidine or heat) to aggregate washed human platelets and release [(3)H]-serotonin from the platelets was investigated and compared with the activity of normal IgG and tetanus-antitetanus IgG antigen-antibody complexes. Aggregated IgG1, IgG2, IgG3, IgG4, and normal IgG complexes all aggregated platelets and caused release of serotonin to similar extents. In contrast, IgA1, IgA2, IgD, and IgE myeloma proteins as well as IgM macroglobulins were completely inactive in this respect. Approximately 50% of the actvity remained in aggregated, mildly reduced and alkylated IgG myeloma proteins and their Fc fragments, whereas aggregated F(ab')(2) fragments were completely inactive. Addition of fresh serum inhibited the release of serotonin caused by aggregated IgG1 and IgG3 proteins and normal IgG antigen-antibody complexes by about 50% but had no effect upon the release of serotonin obtained with IgG2 and IgG4 proteins. This inhibition appeared to be mediated by complement. The release of serotonin was not accompanied by liberation of the cytoplasmic enzyme lactic dehydrogenase, indicating that no significant lysis of the platelets occurred. Addition of neutrophils did not enhance the serotonin release.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4700496      PMCID: PMC302385          DOI: 10.1172/JCI107296

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

Authors:  T Ishizaka; K Ishizaka; S Salmon; H Fudenberg
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

2.  Structural studies of human gamma D myeloma protein.

Authors:  H L Spiegelberg; J W Prahl; H M Grey
Journal:  Biochemistry       Date:  1970-05-12       Impact factor: 3.162

3.  Immune reactions of human blood platelets. II. The effect of latex particles coated with gammaglobulin in relation of complement activation.

Authors:  C Mueller-Eckhardt; E F Lüscher
Journal:  Thromb Diath Haemorrh       Date:  1968-11-15

4.  The production of antisera to human gammaGlobulin subclasses in rabbits using immunological unresponsiveness.

Authors:  H L Spiegelberg; W O Weigle
Journal:  J Immunol       Date:  1968-08       Impact factor: 5.422

5.  Immune reactions of human blood platelets. I. A comparative study on the effects on platelets of heterologous antiplatet antiserum, antigen-antibody complexes, aggregated gammaglobulin and thrombin.

Authors:  C Mueller-Eckhardt; E F Lüscher
Journal:  Thromb Diath Haemorrh       Date:  1968-11-15

6.  The effect of plasma proteins on the interaction of platelets with glass surfaces.

Authors:  M A Packham; G Evans; M F Glynn; J F Mustard
Journal:  J Lab Clin Med       Date:  1969-04

7.  The adherence of leucocytes and platelets induced by fixed IgG antibody or complement.

Authors:  P M Henson
Journal:  Immunology       Date:  1969-01       Impact factor: 7.397

8.  Immune reactions of human blood platelets. 3. Inhibition of immune reactions by sulfhydryl reagents.

Authors:  C Mueller-Eckhardt; E F Lüscher
Journal:  Thromb Diath Haemorrh       Date:  1968-12-31

9.  Mechanisms of release of constituents from rabbit platelets by antigen-antibody complexes and complement. I. Lytic and nonlytic reactions.

Authors:  P M Henson
Journal:  J Immunol       Date:  1970-08       Impact factor: 5.422

10.  Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses. I. Catabolism of gammaG-myeloma proteins in man.

Authors:  H L Spiegelberg; B G Fishkin; H M Grey
Journal:  J Clin Invest       Date:  1968-10       Impact factor: 14.808

View more
  40 in total

Review 1.  Platelet-bacterial interactions.

Authors:  Steven W Kerrigan; Dermot Cox
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

2.  Release of platelet constituents by monosodium urate crystals.

Authors:  M H Ginsberg; F Kozin; M O'Malley; D J McCarty
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

3.  [Relations between complement and blood coagulation (author's transl)].

Authors:  G Müller-Berghaus
Journal:  Klin Wochenschr       Date:  1977-07-15

4.  Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G.

Authors:  A Moore; G D Ross; R L Nachman
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

5.  Synergistic platelet activation by aggregates of IgG and the phospholipid platelet-activating factor 1-O-alkyl-2-acetyl-SN-glycero-3-phosphorylcholine.

Authors:  F H Valone
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

6.  Platelet stimulation by antifibronectin antibodies requires the Fc region of antibody.

Authors:  D Holderbaum; L A Culp; H B Bensusan; H Gershman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

7.  Platelet-aggregating immune complexes and intraplatelet serotonin in idiopathic glomerulonephritis and systemic lupus.

Authors:  N Kasai; A Parbtani; J S Cameron; V Yewdall; P Shepherd; P Verroust
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

8.  Immunoinhibition of ristocetin-induced platelet aggregation.

Authors:  R L Nachman; E A Jaffe; B B Weksler
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

9.  Relative importance of total versus external platelet-associated IgG.

Authors:  U E Nydegger; J P Buchs; L Borradori
Journal:  Blut       Date:  1989-07

10.  Platelets in the synovial fluid of patients with rheumatoid arthritis.

Authors:  M Farr; A Wainwright; M Salmon; C A Hollywell; P A Bacon
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.